EP4499066A4 - PSYCHOACTIVE MEDICINES AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC AND NEUROLOGICAL DISORDERS AND DISORDERS - Google Patents

PSYCHOACTIVE MEDICINES AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC AND NEUROLOGICAL DISORDERS AND DISORDERS

Info

Publication number
EP4499066A4
EP4499066A4 EP23781540.2A EP23781540A EP4499066A4 EP 4499066 A4 EP4499066 A4 EP 4499066A4 EP 23781540 A EP23781540 A EP 23781540A EP 4499066 A4 EP4499066 A4 EP 4499066A4
Authority
EP
European Patent Office
Prior art keywords
psychiatric
disorders
treatment
neurological diseases
psychoactive drugs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP23781540.2A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP4499066A1 (en
Inventor
Blake Mandell
Martin Stogniew
Jennifer Louise Schmidt
Markus Seelig
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Transcend Therapeutics Inc
Original Assignee
Transcend Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2022/074369 external-priority patent/WO2023015154A1/en
Application filed by Transcend Therapeutics Inc filed Critical Transcend Therapeutics Inc
Publication of EP4499066A1 publication Critical patent/EP4499066A1/en
Publication of EP4499066A4 publication Critical patent/EP4499066A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP23781540.2A 2022-03-31 2023-02-02 PSYCHOACTIVE MEDICINES AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC AND NEUROLOGICAL DISORDERS AND DISORDERS Pending EP4499066A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263325757P 2022-03-31 2022-03-31
US202263328343P 2022-04-07 2022-04-07
PCT/US2022/074369 WO2023015154A1 (en) 2021-08-06 2022-08-01 Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders
US202363437000P 2023-01-04 2023-01-04
PCT/US2023/012196 WO2023191952A1 (en) 2022-03-31 2023-02-02 Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders

Publications (2)

Publication Number Publication Date
EP4499066A1 EP4499066A1 (en) 2025-02-05
EP4499066A4 true EP4499066A4 (en) 2026-02-18

Family

ID=88203364

Family Applications (1)

Application Number Title Priority Date Filing Date
EP23781540.2A Pending EP4499066A4 (en) 2022-03-31 2023-02-02 PSYCHOACTIVE MEDICINES AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC AND NEUROLOGICAL DISORDERS AND DISORDERS

Country Status (10)

Country Link
EP (1) EP4499066A4 (https=)
JP (1) JP2025510790A (https=)
KR (1) KR20240165982A (https=)
CN (1) CN119095593A (https=)
AU (1) AU2023241546A1 (https=)
CA (1) CA3254727A1 (https=)
IL (1) IL315832A (https=)
MX (1) MX2024012095A (https=)
TW (1) TW202345789A (https=)
WO (1) WO2023191952A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120379978A (zh) * 2022-10-20 2025-07-25 创见疗法股份有限公司 苯乙胺和卡西酮及其立体异构体与其前体的制备

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996039133A1 (en) * 1995-06-06 1996-12-12 Neurobiological Technologies, Inc. Novel n-substituted-2-amino-3',4'-methylene-dioxypropiophenones
WO2022212854A1 (en) * 2021-04-01 2022-10-06 Terran Biosciences Inc. Methods and compositions relating to psychedelics and serotonin receptor modulators
WO2023019369A1 (en) * 2021-08-20 2023-02-23 Pharmala Biotech Inc. Compositions comprising non-racemic mixtures of (r)- and (s)-3,4-methylenedioxymethamphetamine or (r) and (s) n-methyl-1,3-benzodioxolylbutanamine and uses thereof
WO2023081403A1 (en) * 2021-11-05 2023-05-11 Terran Biosciences Inc. Isotopologes, salts, crystalline forms, stereoisomers, of methylone and ethylone and methods of use thereof
WO2023081899A1 (en) * 2021-11-05 2023-05-11 Terran Biosciences, Inc. Isotopically enriched n-methyl-1,3-benzodioxolylbutanamine (mbdb) and stereoisomers thereof
WO2023107715A1 (en) * 2021-12-09 2023-06-15 Tactogen Inc Specialized combinations for mental disorders or mental enhancement

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8575194B1 (en) * 2004-08-31 2013-11-05 Jack William Schultz Treatment methods of cognitive, emotional and mental ailments and disorders
EP2931291B1 (en) * 2012-12-11 2021-10-20 The McLean Hospital Corporation Xenon treatment as an adjunct to psychotherapy for psychiatric disorders
WO2017151980A1 (en) * 2016-03-03 2017-09-08 Segreti Louis M Cannabis-based bioactive formulations and methods for use thereof
WO2021257500A1 (en) * 2020-06-17 2021-12-23 Lobe Sciences Ltd. Methods and compositions for treating mild traumatic brain injury, post-traumatic stress disorder and mild traumatic brain injury with post traumatic stress disorder
MX2024001654A (es) * 2021-08-06 2024-06-28 Transcend Therapeutics Inc Medicamentos psicoactivos y su uso para el tratamiento de enfermedades y trastornos psiquiatricos y neurologicos.

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996039133A1 (en) * 1995-06-06 1996-12-12 Neurobiological Technologies, Inc. Novel n-substituted-2-amino-3',4'-methylene-dioxypropiophenones
WO2022212854A1 (en) * 2021-04-01 2022-10-06 Terran Biosciences Inc. Methods and compositions relating to psychedelics and serotonin receptor modulators
WO2023019369A1 (en) * 2021-08-20 2023-02-23 Pharmala Biotech Inc. Compositions comprising non-racemic mixtures of (r)- and (s)-3,4-methylenedioxymethamphetamine or (r) and (s) n-methyl-1,3-benzodioxolylbutanamine and uses thereof
WO2023081403A1 (en) * 2021-11-05 2023-05-11 Terran Biosciences Inc. Isotopologes, salts, crystalline forms, stereoisomers, of methylone and ethylone and methods of use thereof
WO2023081899A1 (en) * 2021-11-05 2023-05-11 Terran Biosciences, Inc. Isotopically enriched n-methyl-1,3-benzodioxolylbutanamine (mbdb) and stereoisomers thereof
WO2023107715A1 (en) * 2021-12-09 2023-06-15 Tactogen Inc Specialized combinations for mental disorders or mental enhancement

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Part 1: Study Protocol", 28 May 2007 (2007-05-28), pages 1 - 53, XP093345775, Retrieved from the Internet <URL:https://maps.org/wp-content/uploads/2011/10/protocol280507.pdf> *
BAHJI ANEES ET AL: "Efficacy of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for posttraumatic stress disorder: A systematic review and meta-analysis", PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, ELSEVIER, GB, vol. 96, 19 August 2019 (2019-08-19), XP085883034, ISSN: 0278-5846, [retrieved on 20190819], DOI: 10.1016/J.PNPBP.2019.109735 *
KARILA LAURENT ET AL: "The effects and risks associated to mephedrone and methylone in humans: A review of the preliminary evidences", BRAIN RESEARCH BULLETIN, ELSEVIER SCIENCE LTD, OXFORD, GB, vol. 126, 16 March 2016 (2016-03-16), pages 61 - 67, XP029753108, ISSN: 0361-9230, DOI: 10.1016/J.BRAINRESBULL.2016.03.005 *
MUELA A T ET AL: "P.1.c.014 MBDB, a recreational drug similar to MDMA, exhibits anxiogenic-like effects in mice tested in the elevated plus-maze", EUROPEAN NEUROPSYCHOPHARMACOLOGY, ELSEVIER SIENCE PUBLISHERS BV , AMSTERDAM, NL, vol. 20, 1 August 2010 (2010-08-01), pages S243, XP027357643, ISSN: 0924-977X, [retrieved on 20100801] *
OERI HANS EMANUEL: "Beyond ecstasy: Alternative entactogens to 3,4-methylenedioxymethamphetamine with potential applications in psychotherapy", JOURNAL OF PSYCHOPHARMACOLOGY., vol. 35, no. 5, 10 September 2020 (2020-09-10), GB, pages 512 - 536, XP093004528, ISSN: 0269-8811, DOI: 10.1177/0269881120920420 *
See also references of WO2023191952A1 *

Also Published As

Publication number Publication date
MX2024012095A (es) 2025-01-09
KR20240165982A (ko) 2024-11-25
IL315832A (en) 2024-11-01
CN119095593A (zh) 2024-12-06
WO2023191952A1 (en) 2023-10-05
CA3254727A1 (en) 2023-10-05
JP2025510790A (ja) 2025-04-15
TW202345789A (zh) 2023-12-01
AU2023241546A1 (en) 2024-10-17
EP4499066A1 (en) 2025-02-05

Similar Documents

Publication Publication Date Title
EP4380588A4 (en) PSYCHOACTIVE DRUGS AND THEIR USE FOR THE TREATMENT OF PATHOLOGICAL CONDITIONS AND PSYCHIATRIC AND NEUROLOGICAL DISORDERS
ZA202212876B (en) 4-oxo-3,4-dihydroquinazolinon compounds for the treatment of braf-associated diseases and disorders
DE602005015451D1 (de) Auf probiotischen bakterien basierende zusammensetzung und ihre verwendung zur vorbeugung und/oder behandlung von atemwegserkrankungen und/oder infektionen sowie zur verbesserung der darmtätigkeit
DE602004010407D1 (de) Fluorsubstituierter omega-carboxyaryldiphenylharnstoff zur behandlung und prävention von krankheiten und leiden
EP4288048A4 (en) OXA-IBOGAIN-INSPIRED ANALOGUES FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS
DE602004022871D1 (de) Nogo-a-neutralisierende immunglobuline zur behandlung neurologischer krankheiten
PL3956310T3 (pl) &lt;div&gt;MODYFIKOWANE POCHODNE AMINOKWASÓW DO LECZENIA CHORÓB NEUROLOGICZNYCH I WYBRANYCH ZABURZEŃ PSYCHICZNYCH&lt;/div&gt;
IL287748A (en) Treatment and detection of inherited neuropathies and associated disorders
IL309317A (en) Treatment of diseases and disorders associated with MTRES1
EP4359405A4 (en) BETA-LACTAM DERIVATIVES FOR TREATING DISEASES
EP4549459A4 (en) AAV MEDICINE FOR TREATING DISEASES OF THE REFUND OF THE EYE ASSOCIATED WITH ANGIOGENESE
EP4196127C0 (en) NICOTINAMIDE MONONUCLEOTIDE DERIVATIVES IN THE TREATMENT AND PREVENTION OF SICKLE CELL DISEASE
EP4288075A4 (en) SELECTIVE INHIBITION OF ROCK2 FOR THE TREATMENT OF EDEMA AND RELATED CONDITIONS
EP4093389A4 (en) Prodrug for the treatment of disease and injury of oxidative stress
EP4499066A4 (en) PSYCHOACTIVE MEDICINES AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC AND NEUROLOGICAL DISORDERS AND DISORDERS
DE60312505D1 (de) Injektion aus ixeris sonchifolia zur behandlung von kardiozerebralen gefässerkrankungen und funduserkrankungen sowie herstellungsverfahren dafür
EP4469059A4 (en) PHARMACEUTICAL COMPOSITIONS OF MYCOPHENOLIC ACID AND/OR BETAMETHASONE FOR THE TREATMENT OF EYE DISORDERS
EP4541881A4 (en) BIFIDOBACTERIUM BIFIDUM FOR THE TREATMENT OF DIABETES AND ASSOCIATED CONDITIONS
EP4430043A4 (en) IMIDAZO[4,5-b]PYRIDINE CRYSTALLINE COMPOUND, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OF MEDICAL CONDITIONS
EP4527387A4 (en) Pharmaceutical composition: Compound for the treatment of glaucoma and its use
EP4359005A4 (en) Psychedelic drug treatment of neuropsychiatric disorders and cerebral palsy
EP4215531A4 (en) COMPOUND FOR PREVENTING AND TREATING LIVER DISEASES AND ITS PHARMACEUTICAL USE
EP4522772A4 (en) TREATMENT OF DISEASES AND DISORDERS WITH MIRACLES MODIFYING COMPOUNDS 4
IL313904A (en) Heteroalicyclic derivatives and their use in the treatment of cns disorders
EP4467140A4 (en) PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF TUMORS AND ITS USE

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20240923

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40120964

Country of ref document: HK

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/36 20060101AFI20251030BHEP

Ipc: A61K 36/185 20060101ALI20251030BHEP

Ipc: A61K 45/06 20060101ALI20251030BHEP

Ipc: A61P 25/26 20060101ALI20251030BHEP

Ipc: A61P 25/22 20060101ALI20251030BHEP

Ipc: A61K 31/138 20060101ALI20251030BHEP

Ipc: A61P 25/24 20060101ALI20251030BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20260115

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/36 20060101AFI20260109BHEP

Ipc: A61K 36/185 20060101ALI20260109BHEP

Ipc: A61K 45/06 20060101ALI20260109BHEP

Ipc: A61P 25/26 20060101ALI20260109BHEP

Ipc: A61P 25/22 20060101ALI20260109BHEP

Ipc: A61K 31/138 20060101ALI20260109BHEP

Ipc: A61P 25/24 20060101ALI20260109BHEP